 |
|
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Wayne Huey-Herng Sheu (Sheu WHH), Siew Pheng Chan (Chan SP), Bien J. Matawaran (Matawaran BJ), Chaicharn Deerochanawong (Deerochanawong C), Ambrish Mithal (Mithal A), Juliana Chan (Chan J), Ketut Suastika (Suastika K), Chin Meng Khoo (Khoo CM), Huu Man Nguyen (Nguyen HM), Ji Linong (Linong J), Andrea Luk (Luk A), Kun-Ho Yoon (Yoon KH)
Diabetes Metab J. 2020;44(1):11-32. Published online 2020 Feb 21 DOI: https://doi.org/10.4093/dmj.2019.0208
|
|
Citations to this article as recorded by
 Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development
Ernest A. Adeghate, Huba Kalász, Saeeda Al Jaberi, Jennifer Adeghate, Kornelia Tekes
Expert Opinion on Investigational Drugs.2021; 30(2): 85. CrossRef Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Jianping Weng, Longyi Zeng, Yuwei Zhang, Shen Qu, Xueying Wang, Ping Li, Liujun Fu, Boqing Ma, Shandong Ye, Jiao Sun, Weiping Lu, Zhiwen Liu, Daoxiong Chen, Zhifeng Cheng, Haiyan Liu, Tao Zhang, Jianjun Zou
Diabetes, Obesity and Metabolism.2021; 23(8): 1754. CrossRef How do you treat obesity in the elderly pharmacologically?
Claudio Daniel González, Guillermo Di Girolamo
Expert Opinion on Pharmacotherapy.2021; 22(13): 1639. CrossRef Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
Ayako Nagayama, Kenji Ashida, Miki Watanabe, Kanoko Moritaka, Aya Sonezaki, Yoichiro Kitajima, Hirokazu Takahashi, Satoko Yoshinobu, Shimpei Iwata, Junichi Yasuda, Nao Hasuzawa, Shuichi Ozono, Seiichi Motomura, Masatoshi Nomura
Frontiers in Endocrinology.2021;[Epub] CrossRef New Pandemic: Obesity and Associated Nephropathy
Isha Sharma, Yingjun Liao, Xiaoping Zheng, Yashpal S. Kanwar
Frontiers in Medicine.2021;[Epub] CrossRef Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective
Hayato Tanabe, Hiroaki Masuzaki, Michio Shimabukuro
Diabetes Research and Clinical Practice.2021; 180: 109067. CrossRef Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Known and unknown
Buchun Jiang, Zhiwen Cheng, Fei Liu, Qiuyu Li, Haidong Fu, Jianhua Mao
Nephrology.2021;[Epub] CrossRef Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
Wayne H‐H Sheu
Journal of Diabetes Investigation.2020; 11(5): 1115. CrossRef SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients André J Scheen
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 2765. CrossRef SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Yoshifumi Saisho
Diseases.2020; 8(2): 14. CrossRef Roles of Epicardial Adipose Tissue in the Pathogenesis of Coronary Atherosclerosis ― An Update on Recent Findings ―
Kimie Tanaka, Daiju Fukuda, Masataka Sata
Circulation Journal.2020; 85(1): 2. CrossRef
|